Menu
About us
Expand menu
Overview
Our people
Meet Us
Our Facilities
News
Sustainability
Integrity and Ethics
Our Services
Expand menu
Overview
Analytics
Process Development
Quality and Regulatory
Manufacturing
Viral Vectors
Expand menu
LentiVector® platform
inAAVate™ platform
Other Viral Vectors
Careers
Knowledge Centre
Investors
Expand menu
Analyst coverage
Registrars
Investor contacts
Share price information
Results, reports, presentations & webcasts
Regulatory news
Shareholder meetings, circulars & prospectuses
Acquisition of ABL Europe (Oxford Biomedica France SAS)
Corporate governance
Board committees
Subsidiaries governance & compliance
Warning to shareholders
Investor Calendar
Get In Touch
About us
Overview
Our people
Meet Us
Our Facilities
News
Sustainability
Integrity and Ethics
Our Services
Overview
Analytics
Process Development
Quality and Regulatory
Manufacturing
Viral Vectors
LentiVector® platform
inAAVate™ platform
Other Viral Vectors
Careers
Knowledge Centre
Investors
Analyst coverage
Registrars
Investor contacts
Share price information
Results, reports, presentations & webcasts
Regulatory news
Shareholder meetings, circulars & prospectuses
Acquisition of ABL Europe (Oxford Biomedica France SAS)
Corporate governance
Board committees
Subsidiaries governance & compliance
Warning to shareholders
Investor Calendar
Get In Touch
Menu
Rapid optimisations for cell & gene therapy application
17 September 2024
Continue reading
